Analysts Set BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) PT at $20.40

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has earned an average rating of “Moderate Buy” from the twelve research firms that are currently covering the stock, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a hold rating and seven have issued a buy rating on the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $20.40.

A number of equities analysts have recently commented on BCRX shares. Needham & Company LLC reissued a “buy” rating and issued a $16.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday, September 8th. Wedbush dropped their price objective on shares of BioCryst Pharmaceuticals from $21.00 to $20.00 and set an “outperform” rating for the company in a report on Thursday, August 6th. Cantor Fitzgerald upped their target price on shares of BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the stock an “overweight” rating in a research report on Tuesday, June 30th. JPMorgan Chase & Co. began coverage on BioCryst Pharmaceuticals in a research note on Monday, July 13th. They issued a “neutral” rating and a $12.00 target price on the stock. Finally, Wall Street Zen downgraded BioCryst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 29th.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

Large investors have recently modified their holdings of the company. Bank of America Corp DE grew its position in BioCryst Pharmaceuticals by 231.6% during the first quarter. Bank of America Corp DE now owns 5,091,765 shares of the biotechnology company’s stock valued at $48,474,000 after acquiring an additional 3,556,208 shares during the last quarter. Pacer Advisors Inc. bought a new stake in shares of BioCryst Pharmaceuticals in the 1st quarter worth approximately $14,880,000. Wedge Capital Management L L P NC bought a new stake in shares of BioCryst Pharmaceuticals in the 2nd quarter worth approximately $3,808,000. ADAR1 Capital Management LLC purchased a new stake in shares of BioCryst Pharmaceuticals in the 2nd quarter valued at $1,330,000. Finally, Rice Hall James & Associates LLC purchased a new stake in shares of BioCryst Pharmaceuticals in the 2nd quarter valued at $23,320,000. 85.88% of the stock is owned by hedge funds and other institutional investors.

BioCryst Pharmaceuticals Trading Up 3.2%

Shares of BCRX opened at $8.70 on Tuesday. BioCryst Pharmaceuticals has a 12-month low of $6.00 and a 12-month high of $11.22. The company has a market cap of $2.22 billion, a PE ratio of -5.80 and a beta of 0.57. The stock has a 50-day moving average price of $9.46 and a 200-day moving average price of $9.25.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its earnings results on Wednesday, August 5th. The biotechnology company reported $0.30 earnings per share for the quarter, beating analysts’ consensus estimates of $0.15 by $0.15. BioCryst Pharmaceuticals had a negative net margin of 40.90% and a negative return on equity of 86.89%. The business had revenue of $218.25 million for the quarter, compared to the consensus estimate of $183.28 million. During the same period last year, the firm posted $0.15 earnings per share. BioCryst Pharmaceuticals’s quarterly revenue was up 33.6% on a year-over-year basis. As a group, analysts predict that BioCryst Pharmaceuticals will post -2.25 earnings per share for the current year.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes orally administered medicines for rare diseases. The company focuses on treatments that address significant unmet medical needs, using expertise in small-molecule drug discovery and development.

BioCryst’s primary commercial product is ORLADEYO (berotralstat), an oral, once-daily medication used to prevent hereditary angioedema attacks in adults and pediatric patients ages 12 and older.